FDA Issues National Priority Vouchers for Three Psychedelic Therapies, Including Silocybin and Methylone
Executive Order and FDA Response
In response to the 'Accelerating Access to Mental Health Care' executive order signed by President Trump on April 18, 2026, the FDA issued Commissioner's National Priority Vouchers for three psychedelic drug programs on April 24. These vouchers provide a significant regulatory incentive, shortening the standard 10-month NDA review period to 1-2 months. This unprecedented move institutionalizes federal priority review for mental health treatments and signals a paradigm shift in the industry, as the administration formally elevates psychedelics to a public health priority.
Three Programs Receiving Priority Vouchers
Compass Pathways (CMPS)' COMP360 (psilocybin) achieved its primary endpoints in both Phase 3 trials for treatment-resistant depression (TRD) (COMP005: MADRS score -3.6 points compared to placebo, p<0.001, n=258; COMP006: 25mg twice daily, highly significant). The rolling NDA submission is scheduled for Q4 2026. Usona Institute (a non-profit) received a voucher for its Phase 3 trial of psilocybin for major depressive disorder (MDD). Transcend Therapeutics (private) is preparing to launch a Phase 3 trial for TSND-201 (methylone) in July 2025, following its Breakthrough Therapy designation for PTSD. TSND-201 is differentiated from other psychedelics due to its 5-HT2A receptor-inactive, non-hallucinogenic neuroplastogen mechanism, offering a distinct safety profile.
DemeRx Noribogaine IND Approval + Regulatory Overhaul
The FDA approved DemeRx NB Inc.'s noribogaine hydrochloride (DMX-1001) for alcohol use disorder (AUD), marking the first Phase 1 IND in the United States. Noribogaine is a metabolite of ibogaine, designed to maintain the anti-addiction effects while reducing the cardiotoxicity (QT interval prolongation) concerns associated with the parent compound. The Department of Justice will initiate an immediate review for rescheduling of Schedule I drugs that complete Phase 3 trials, as mandated by the executive order. HHS will allocate USD 50 million through ARPA-H to accelerate clinical trials of ibogaine. The FDA's final guidance on 5-HT2A agonists is also expected soon, which will clarify the criteria for clinical trial design.
Market Size and Competitive Landscape
The psychedelic therapeutics market is estimated at USD 3.4-7.4 billion in 2026 (varying by research firm) and is projected to grow to over USD 11 billion by 2034. The existing standard of care for TRD is J&J's Spravato (esketamine, nasal spray), and Axsome Therapeutics (AXSM) has secured approval for Auvelity (dextromethorphan/bupropion) for MDD. In the generalized anxiety disorder (GAD) space, Definium Therapeutics (DFTX, formerly MindMed) is simultaneously conducting two Phase 3 trials (Voyage and Panorama) of MM120 (lysergic acid D-tartrate, LSD) and received Breakthrough Therapy designation in May 2026.
Risk Factors
The cardiotoxicity associated with ibogaine requires continuous close clinical monitoring and poses challenges for commercialization. The psychedelic-assisted therapy model requires specialized training for practitioners and infrastructure for treatment settings, which may limit its scalability compared to standard drugs. Rescheduling of Schedule I drugs requires separate consultation with the DEA, which introduces timeline uncertainty. The industry is also monitoring the potential risk that accelerated regulatory pathways could compromise safety verification in vulnerable patient populations.
The issuance of National Priority Vouchers is expected to shorten the NDA review period for Compass Pathways (CMPS)' COMP360 from 10 months to 1-2 months, increasing the likelihood of approval by the first half of 2027 and serving as a short-term catalyst for the stock. The psychedelic therapeutics market is projected to grow to over USD 11 billion by 2034, and J&J's Spravato, with annual sales of approximately USD 900 million, can be used as a benchmark to gauge the potential market penetration of silocybin-based therapies. The requirement for immediate review of rescheduling for Schedule I drugs upon completion of Phase 3 trials institutionalizes a DEA-FDA collaboration pathway, structurally reducing clinical investment risk across the industry. The imminent release of the final guidance on 5-HT2A agonists will necessitate the revision of clinical design and IND submission strategies, and is expected to accelerate the competition for Breakthrough Therapy designations among Phase 2 companies. HHS ARPA-H's USD 50 million investment in ibogaine research will serve as a federal direct funding channel for early-stage, private companies, potentially creating a venture capital leverage effect.